Company Encyclopedia
View More
name
Wantai Biological
603392.SH
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells in vitro diagnostic reagents and instruments, and vaccines in China and internationally. It operates through Diagnostics Division and Vaccine Division segments. The company offers chemiluminescence detection, biochemical, hepatitis B core antibody detection, and HIV reagents; rapid urine tests for hepatitis E antigen; chronic disease management, hepatitis E screening and prevention, women’s full life-cycle health management, smart laboratories, medical laboratory quality and competence accreditation, lean management consulting, blood safety testing, and internal quality control solutions; enzyme-linked immunosorbent assay, colloidal gold, nucleic acid, clinical test quality control products, and raw materials; and nucleic acid testing devices.
1.581 T
603392.SHMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking61/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-2.72%D
    • Profit Margin-18.59%D
    • Gross Margin48.65%B
  • Growth ScoreE
    • Revenue YoY-27.89%E
    • Net Profit YoY-13.54%D
    • Total Assets YoY-2.50%D
    • Net Assets YoY-2.67%D
  • Cash ScoreE
    • Cash Flow Margin-537.89%E
    • OCF YoY-27.89%E
  • Operating ScoreE
    • Turnover0.12E
  • Debt ScoreA
    • Gearing Ratio14.60%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | Tonix Pharmaceuticals Holding experiences significant intraday volatility, is a rebound trend about to start?

    Tonix Pharmaceuticals Holdings (TNXP.US) showed a significant surge in trading volume yesterday, with the previously stagnant small-cap pharmaceutical stocks experiencing a return of institutional investors, and community FOMO sentiment gradually rising. The stock price broke through short-term moving average resistance, igniting trading enthusiasm in the morning session, as bulls attempted to dominate the market. Although there are currently no major favorable policies in the pharmaceutical industry, speculation surrounding vaccine development and industry policy adjustments has resurfaced, transmitting to the small-cap biotech sector, where capital competition is rapidly heating up. Institutions quickly built positions and lifted prices in the low volatility zone, raising short-term attention. Technically, the daily K-line formed a large bullish candle, breaking through the upper band of the moving average system, with the MACD indicator also turning upward. The main funds made three upward pushes in intraday trading, with sufficient follow-up capital, indicating strong momentum. Today, attention should be paid to whether the gentle increase in volume can be sustained. If the short-term enthusiasm for chasing prices continues, it may ignite a rally in small-cap pharmaceutical stocks. Caution is needed against potential follow-up buying failing to sustain, which could lead to a quick cooling of the market as institutions take profits. For right-side traders, Tonix's intraday volatility today is an important signal for the initiation of a rebound trend

    Technical Forecast·
    SZ
    300142
    -1.11%
    SH
    688185
    -0.69%
    HK
    06185
    -2.04%
    Technical Forecast·
    SZ
    300142
    -1.11%
    SH
    688185
    -0.69%
    HK
    06185
    -2.04%

    Sinovac: Signed a ten-year vaccine cooperation agreement with the Brazilian Ministry of Health, creating the largest international order for Chinese vaccines

    Sinovac has signed a ten-year vaccine cooperation agreement with the Brazilian Ministry of Health, becoming the first Chinese vaccine company to win the bid for this project. Sinovac will collaborate with Brazil's Tecpar Institute and Eurofarma to provide approximately 60 million doses of varicella and rabies vaccines to Brazil over the next ten years, with a contract amount exceeding 700 million USD, setting a record for the largest international order for a Chinese vaccine company

    Wallstreetcn·
    SH
    688185
    -0.69%
    HK
    06185
    -2.04%
    SH
    603392
    +1.42%
    Wallstreetcn·
    SH
    688185
    -0.69%
    HK
    06185
    -2.04%
    SH
    603392
    +1.42%

    Kangtai Biological: Quadrivalent Influenza Virus Split Vaccine Starts Phase I Clinical Trial

    Kangtai Biological announced that its developed quadrivalent influenza virus split vaccine has completed preparations for Phase I clinical trials, which have now commenced, and the first subject has been successfully enrolled. The vaccine is suitable for individuals aged 6 to 35 months and aims to stimulate immunity to prevent influenza virus. The trial employs a single-center, randomized, blind, positive control design to evaluate the vaccine's safety and preliminary immunogenicity

    Zhitong·
    SH
    603392
    +1.42%
    Zhitong·
    SH
    603392
    +1.42%

    Huachuang Securities: In the first three quarters, most vaccine varieties saw year-on-year growth in batch approvals, and pet vaccines continued to maintain a high growth rate

    Huachuang Securities released a research report stating that in the first three quarters of 2023, the batch issuance volume of most vaccine varieties increased year-on-year, especially with outstanding performance in pet vaccines and ruminant vaccines. Despite the pressure of internal competition in the animal husbandry industry, the prices of veterinary raw materials have stabilized and rebounded. Focus on undervalued and resilient targets. Specific data shows significant growth in pig vaccines, poultry vaccines, and pet vaccines, reflecting the positive impact of farming profitability and the launch of new products

    Zhitong·
    SH
    603392
    +1.42%
    SH
    600201
    -0.69%
    SH
    603566
    +0.08%
    Zhitong·
    SH
    603392
    +1.42%
    SH
    600201
    -0.69%
    SH
    603566
    +0.08%

    Some vaccination sites for the flu vaccine have "appointments but no vaccines," with price trends for different tiers of vaccines diverging

    Recently, reporters conducted research in Nanjing, Shenzhen, Chengdu, and other places and found that the flu vaccine vaccination wave has arrived this year. The number of people getting vaccinated at community hospitals has increased, leading to some vaccination sites having "appointments but no vaccines." The types of vaccines administered are mainly domestic vaccines. In terms of price, since the beginning of the year, the government procurement price of the trivalent vaccine has continued to decline, even reaching a "floor price" of 5.5 yuan per dose, while the price of the self-paid quadrivalent vaccine has remained stable this year

    Zhitong·
    SZ
    300142
    -1.11%
    SH
    688185
    -0.69%
    HK
    06185
    -2.04%
    Zhitong·
    SZ
    300142
    -1.11%
    SH
    688185
    -0.69%
    HK
    06185
    -2.04%
    © 2025 Longbridge｜Disclaimer